JORGE CASTILLO to Immunotherapy
This is a "connection" page, showing publications JORGE CASTILLO has written about Immunotherapy.
Connection Strength
1.749
-
Novel Agents in Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2023 08; 37(4):751-760.
Score: 0.589
-
Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. J Natl Compr Canc Netw. 2016 09; 14(9):1121-9.
Score: 0.370
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
Score: 0.168
-
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy. Cancer Rep (Hoboken). 2024 Sep; 7(9):e2126.
Score: 0.161
-
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
Score: 0.118
-
Comparative outcomes of immunochemotherapy regimens in Waldenstr?m macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115.
Score: 0.098
-
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr?m macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
Score: 0.092
-
Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014 Aug; 38(8):866-73.
Score: 0.079
-
Cellular immunotherapy for refractory hematological malignancies. J Transl Med. 2013 Jun 19; 11:150.
Score: 0.074